Fig. 6From: Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1Proportion of patients with NEDA status up to 1 year. Based on a logistic model adjusting for age (< 40 vs. ≥40 years), sex, baseline EDSS (≤3.5 vs. > 3.5), number of relapses in 2 years prior to screening, and time since MS onset. Active T2 lesions obtained at 6-month and 1-year scans were used. aNEDA defined as no relapses, no 3-month confirmed disability progression, and no active T2 lesions over 1 year; disability progression was defined as a 1-point increase in EDSS score if the baseline EDSS score was < 6.0 or 0.5-point increase if the baseline EDSS score was ≥6.0. (EDSS score could be > 5 if scores increase between screening and baseline.). bNEDA-2, defined as NEDA with relapses defined as Scripps-assessed moderate and/or severe. cNEDA-3, defined as NEDA with relapses defined as Scripps-assessed severe. EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; NEDA: no evidence of disease activity; OR: odds ratio; SC: subcutaneously; tiw: three times weeklyBack to article page